PASG News and Press, Passage Bio Inc. From 05/11/21

Passage Bio collaborator University of Pennsylvania’s Gene Therapy Program to present poster regarding development of a novel mouse model for evaluating efficacy of adeno-associated virus gene therapy for metachromatic leukodystrophy (MLD) Passage Bio gene therapy candi...

PHILADELPHIA, May 10, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc . (Nasdaq: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced it will host its second virtual Research &...

Passage Bio, Inc. (PASG) Q1 2021 Earnings Conference Call May 5, 2021 08:30 AM ET Company Participants Stuart Henderson - Vice President of Investor Relations and Strategic Finance Bruce Goldsmith - President and Chief Executive Officer Richard Morris - Chief Financial Officer Eliseo Salinas ...

Passage Bio (PASG): Q1 GAAP EPS of -$0.76 misses by $0.04.Press Release For further details see: Passage Bio EPS misses by $0.04

Dosed first patient with infantile GM1 gangliosidosis in Imagine-1 Phase 1/2 trial of PBGM01, initial safety and 30-day biomarker data expected 4Q21 Received multiple regulatory clearances for clinical trial initiations for three most advanced pipeline programs Expected ...

Passage Bio (PASG) collaborates with InformedDNA, a genetics services organization to provide no-cost genetic counseling and testing for adults diagnosed with Frontotemporal Dementia ((FTD)), a debilitating form of early onset dementia. The testing program will facilitate ident...

No-cost genetic screening and counseling program aimed at identifying FTD patients who have certain inherited genetic mutations to guide early treatment intervention and awareness of clinical trials Passage Bio is evaluating gene therapy candidate, PBFT02, for treatment of FTD...

PHILADELPHIA, April 29, 2021 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a genetic medicines company focused on developing transformative therapies for rare, monogenic central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a....

Passage Bio (PASG) shares up nearly 12% premarket after the company announces that the European Commission has granted Orphan designation for PBKR03, an adeno-associated virus ((AAV))-delivery gene therapy for the treatment of Krabbe disease (Globoid Cell Leukodystrophy), a rar...

- Krabbe disease, a rare lysosomal storage disorder, has no approved disease-modifying treatment options - Urgency for effective treatment underscored by European Commission designation for investigational gene therapy PBKR03 - Global Phase 1/2 trial – GALax-C &...